OBJECTIVE. The purpose of this study was to evaluate the role of CT perfusion in monitoring response to neoadjuvant antiangiogenic and radiation therapy in resectable soft-tissue @entity242 and correlate the findings with @entity5 size, circulating and @entity5 biomarkers, and gene expression. SUBJECTS AND METHODS. This phase II clinical trial included 20 @entity1 (13 @entity1 and 7 @entity1 ; mean age, 55 years) with soft-tissue @entity242 who were undergoing treatment with the antiangiogenic drug bevacizumab followed by bevacizumab, radiation, and surgical resection. The @entity1 underwent CT perfusion and diagnostic contrast-enhanced CT at baseline, at 2 weeks after bevacizumab therapy, and after completion of bevacizumab and radiation therapy. Multiple CT perfusion parameters (blood flow, blood volume, mean transit time, and permeability) were correlated with @entity5 size, circulating and @entity5 biomarkers, and gene expression. RESULTS. Two weeks after bevacizumab therapy, there was substantial fall in blood volume (31.9% reduction, p = 0.01) with more pronounced reduction in blood flow, blood volume, and permeability after treatment completion (53-64% reduction in blood flow, blood volume, and permeability; p = 0.001), whereas @entity5 size showed no significant change (p = 0.34). @entity5 with higher baseline blood volume and lower baseline @entity5 size showed superior response to bevacizumab and radiation (p = 0.05). There was also an increase in median plasma @entity7 and placental-derived growth factor concentration after bevacizumab therapy paralleled by a decrease in @entity5 perfusion depicted by CT perfusion, although this was not statistically significant (p = 0.4). The baseline @entity5 @entity2101 ( @entity2101 ) correlated with blood flow (p = 0.04). At least 20 different genes were differentially expressed in @entity5 with higher and lower baseline perfusion. CONCLUSION. CT perfusion is more sensitive than @entity5 size for monitoring early and late response to bevacizumab and radiation therapy. CT perfusion parameters correlate with @entity2101 , and the gene expression levels of baseline @entity5 could potentially predict treatment response.

CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue XXXX : Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'tumors'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['microvessel density', 'MVD']
@entity242 :: (MESH:D012509,Disease) :: ['Sarcomas']
